SCHEMBL6317801

SCHEMBL6317801

COc1ccc(C(=O)Nc2onc(-c3ccsc3)c2C(N)=O)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.50
NPC1 O15118 9/20 0.50
KMT2A Q03164 4/20 0.46
TP53 P04637 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALDH1A1 P00352 3/20 0.44
GAA P10253 2/20 0.44
MAPT P10636 2/20 0.44
MITF O75030 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 2/20 0.44
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RAD52 P43351 1/20 0.43
BACE1 P56817 1/20 0.43
MEN1 O00255 2/20 0.42
KLF5 Q13887 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28753347 0.86 RAB9A (0.44) RAB9ANPC1KMT2ATP53SMN1; SMN2
SCHEMBL6316808 0.85 SMN1; SMN2 (0.50) RAB9ANPC1KMT2ATP53SMN1; SMN2
SCHEMBL6315689 0.83 FLT3 (0.48) RAB9ANPC1KMT2ATP53SMN1; SMN2
SCHEMBL6315760 0.83 KMT2A (0.54) RAB9ANPC1KMT2ATP53SMN1; SMN2
SCHEMBL6321934 0.82 NPC1 (0.49) RAB9ANPC1KMT2ATP53SMN1; SMN2
SCHEMBL27591789 0.81 RAB9A (0.45) RAB9ANPC1KMT2ATP53SMN1; SMN2
SCHEMBL6316204 0.78 NPC1 (0.39) RAB9ANPC1TP53ALDH1A1GAA
SCHEMBL6322761 0.78 FLT3 (0.45) RAB9ANPC1KMT2ATP53SMN1; SMN2
SCHEMBL6317596 0.77 RXFP1 (0.53) RAB9AALDH1A1RXFP1
SCHEMBL6317872 0.76 NPC1 (0.44) RAB9ANPC1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RAB9A 1754/4885NPC1 3741/4885KMT2A 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.